Thrivent Financial for Lutherans Trims Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Thrivent Financial for Lutherans trimmed its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 3.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,854 shares of the company’s stock after selling 771 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.07% of Krystal Biotech worth $3,614,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. CANADA LIFE ASSURANCE Co lifted its stake in Krystal Biotech by 80.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 3,128 shares of the company’s stock worth $557,000 after purchasing an additional 1,397 shares in the last quarter. Lazard Asset Management LLC raised its position in shares of Krystal Biotech by 27.5% in the first quarter. Lazard Asset Management LLC now owns 1,308 shares of the company’s stock worth $232,000 after buying an additional 282 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in Krystal Biotech by 54.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 658,618 shares of the company’s stock valued at $117,189,000 after buying an additional 231,255 shares during the period. Caxton Associates LP purchased a new position in Krystal Biotech during the first quarter worth about $232,000. Finally, Virtu Financial LLC bought a new position in Krystal Biotech in the 1st quarter worth about $640,000. 86.29% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $197.76, for a total transaction of $4,944,000.00. Following the completion of the sale, the insider now owns 1,500,882 shares of the company’s stock, valued at approximately $296,814,424.32. This represents a 1.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 14.10% of the company’s stock.

Krystal Biotech Stock Up 2.2 %

Shares of NASDAQ:KRYS opened at $194.56 on Tuesday. The stock has a market cap of $5.60 billion, a PE ratio of 109.92 and a beta of 0.82. The company’s fifty day moving average is $179.55 and its 200 day moving average is $182.80. Krystal Biotech, Inc. has a 52 week low of $99.00 and a 52 week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 4th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.84 by $0.07. Krystal Biotech had a return on equity of 7.54% and a net margin of 21.68%. The firm had revenue of $83.84 million for the quarter, compared to the consensus estimate of $82.94 million. During the same quarter in the previous year, the business earned ($0.67) earnings per share. The company’s quarterly revenue was up 879.9% on a year-over-year basis. Sell-side analysts anticipate that Krystal Biotech, Inc. will post 2.97 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on KRYS shares. Stifel Nicolaus lifted their price target on Krystal Biotech from $204.00 to $220.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Evercore ISI increased their price target on shares of Krystal Biotech from $201.00 to $206.00 and gave the stock an “outperform” rating in a report on Monday, August 12th. Chardan Capital lifted their price objective on shares of Krystal Biotech from $153.00 to $208.00 and gave the stock a “buy” rating in a report on Monday, August 5th. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a research report on Friday, August 30th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Tuesday, November 5th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $202.29.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).